Evotec SE

1EVT

Company Profile

  • Business description

    Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

  • Contact

    Essener Bogen 7
    Manfred Eigen Campus
    Hamburg22419
    DEU

    T: +49 40560810

    E: [email protected]

    https://www.evotec.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2025

    Employees

    4,766

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,756.6039.40-0.45%
CAC 407,765.1110.79-0.14%
DAX 4023,771.45177.45-0.74%
Dow JONES (US)42,967.62101.850.24%
FTSE 1008,884.9220.570.23%
HKSE23,866.86168.52-0.70%
NASDAQ19,662.4846.610.24%
Nikkei 22537,689.16483.93-1.27%
NZX 50 Index12,526.07123.03-0.97%
S&P 5006,045.2623.020.38%
S&P/ASX 2008,533.9031.20-0.36%
SSE Composite Index3,378.0124.64-0.72%

Market Movers